Background. The purpose of this report is to describe our initial experience with a tiered-therapy, variable detection criteria, multiprogrammable antiarrhythmia device capable of antitachycardia pacing, cardioversion, and defibrillation in 50 cardiac arrest survivors.
M ultiprogrammable, tiered-therapy antiarrhythmia devices offer new diagnostic and therapeutic alternatives not available with the earlier generations of implantable defibrillators. [1] [2] [3] [4] [5] [6] [7] The most important advance in device therapy is the option to treat monomorphic ventricular tachycardia (VT) with antitachycardia pacing maneuvers. This option allows the physician to eliminate the pain associated with shock termination of VT and decreases dependency on antiarrhythmic drugs.
The newer implantable devices also can discriminate atrial fibrillation (AF) from VT based on the use of a cycle length stability algorithm. [8] [9] [10] In addition, separate detection zones for slow and for fast ventricular tachyarrhythmias allow the physician to stage the aggressiveness FIGURE 1 .Chestx-rays ofa patient with a transvenouls defibrillator using a coronary sinus (CS) -right ventricular (RV) -subcutaneouls chest patch (CP), three-electrode system (patient was resuscitated from ventricular fibrillation in association with idiopathic dilated cardiomyopathy). The CS lead served as the cathode forsequentialpulse defibrillation to the RVlead as thefirst anode and subsequentl to the CP lead as the second anode. This electrode configuration represents the lead system most frequentl inserted because it usuall provided the lowest implant defibrillation thresholds. dial lead systems were used in 35 patients and transvenous lead systems in 15.
The epicardial lead system consisted of two pace/ sense screw-in electrodes in conjunction with two or three epicardial patch electrodes. Whenever possible, a three-patch epicardial lead system was inserted to lower defibrillation thresholds.'3 Two epicardial patches were used when anatomic considerations limited epicardial access. The epicardial patch electrodes (Medtronic No. 6897) were available in three sizes: 40 cm2, 56 cm2, and 73 cm2. These leads were composed of a helical platinum-iridium coil embedded in a polyurethane matrix. Pacing and sensing with the epicardial lead system was conducted with standard epicardial screw-in electrodes (Medtronic No. 6917A).
The transvenous lead system consisted of three electrodes ( Figure 1 ). One electrode used in all circumstances was a 10.5F right ventricular (RV) tripolarpace, sense, and defibrillation lead (Medtronic model 6884). This lead had an active fixation cathodal screw-in electrode and an anodal ring electrode used for sensing. Proximal to these two electrodes was a 5-cm-long coil electrode used for cardioversion and defibrillation as well as for pacing in conjunction with the screw-in electrode. A 56-cm2 subcutaneous chest patch (CP) electrode (Medtronic model 6895) was the second lead available for transvenous defibrillation. In addition to the RV catheter and subcutaneous patch leads, a 6.5F, 5-cm-long catheter electrode (Medtronic model 6881) could be used for cardioversion-defibrillation purposes when inserted in either the coronary sinus (CS) or the superior vena cava (SVC), depending on CS accessibility and the results of defibrillation testing. The transvenous lead combination ultimately selected was dictated in part by accessibility to the CS, a preferred location in most patients in our experience, and by empiric measurements of defibrillation efficacy.14-17 Details of the defibrillation testing methods used in this study have been described previously. [13] [14] [15] [16] 18, 19 Arrhythmia detection parameters were programmed to optimize therapy and to take advantage of differences in the detection algorithms for VT and VF.9-Noninvasive programmed electrical stimulation via a telemetry link to the device ( Figure 2 ) facilitated detection algorithm programming. When using the VT detection algorithm, device identification of VT was dependent on counting consecutive beats having a cycle length less than a programmable criterion termed the tachycardia detection interval (TDI). The minimum number of intervals one could choose to satisfy the VT detection criterion ranged from four to 128. The continued presence of VT after charging was required before delivery of therapy.
The VF detection algorithm, on the other hand, was more forgiving. The use of an auto-adjusting sensitivity threshold compensated for the variation in VF signal amplitude.2021 In addition, VF detection required that only three fourths of the VF intervals fall below the programmable fibrillation detection interval (FDI). The minimum number of intervals one could choose for VF detection ranged from six to 48. Unlike the VT detection algorithm, VF confirmation was intentionally eliminated to avoid delays in VF therapy. It was reasoned that false positive VF detections of nonsustained VT would be preferential to prolonged hypotension result-FIGURE 2. Tracing of induction of monomorphic ventricular tachycardia (VT) using the programmed electrical stimulation (PES) capabilities of the implantable device. Top tracing is a surface electrocardiogram (ECG) shown in conjunction with a marker channel output indicating how the unit was processing data. PES with triple extrastimuli induces monomorphic VT with a cycle length of 330 msec. From left to right, markers first indicate a normal sensed event during normal sinus rhythm and then indicate paced event markers during PES. Once VT is initiated, the marker channel continues to indicate a normal sensed event until the device is activated, as indicated by the upright cancel magnet (CM) marker. Before this point, the magnet suspended VT detection; thereafter, the marker channel output shows characteristic VT detect markers, negative double deflections ofequal amplitude to those of normal detect markers.
ing from confirmation delays during true VF. In the case of VT, minor delays were deemed more tolerable.
The detection algorithm for VT could be made more rhythm specific by the use of a cycle length stability criterion to avoid therapy of AF ( Figure 3 ). This stability algorithm takes advantage of the intrinsic variability in cycle length during AF in contrast to the cycle length FIGURE 3. After device implantation, the unit was programmed according to data acquired at the implant and follow-up electrophysiology procedures. Thereafter, the patients were seen at 3-month intervals when asymptomatic. Patients aware of device intervention were seen immediately, and the device memory was examined (Figure 4) .
Although intraoperative and predischarge testing were used to program the device in the most suitable fashion, data reflecting device efficacy were derived only from spontaneous events. Historical, examination, and laboratory data were combined with device memory data to determine whether arrhythmia detection was appropriate and to evaluate the efficacy of each mode of therapy.
Two methods for antitachycardia pacing of monomorphic VT were available: self-adaptive burst pacing ( Figure 5 ) and autodecremental overdrive pacing (Figure 6 ). The exact form of antitachycardia pacing varied for each patient, depending on electrophysiological testing and clinical circumstances. Antitachycardia pacing was only used in patients who had clinical or inducible monomorphic VT.
When the device was programmed in the self-adaptive burst pacing mode, it was capable of delivering 1-15 stimuli at 50-97% of the VT cycle length to a programmable minimum pacing cycle length of 150-400 msec. Antitachycardia pacing could be repeated up to 15 times per episode. Repetitive attempts could be made to occur 0-70 msec earlier in the VT diastolic interval when desired. Burst pacing parameters selected in our population were limited to two to 10 stimuli delivered at FIGURE 5. Tracing shows self-adaptive burst pacing terminating an episode of ventricular tachycardia (VT). After induction of VT with programmed electrical stimulation, the device detection algorithm is activated at the cancel magnet (CM) marker, allowing VT detection to begin. Sixteen consecutive intervals less than a 400-msec tachycardia detection interval (TDI) satisfy the VT detection algorithm in this instance. A burst of six pacing stimuli delivered at coupling intervals of 84% of the VT cycle length (CL) terminates VT. The patient's underlying rhythm is atrial fibrillation.
69-87% of the VT cycle length to a minimum of 200-250 msec for up to five attempts. When VT persisted, the train of stimuli was programmed to intervene earlier in the VT diastolic interval by [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] number of stimuli selected in our population ranged between three and nine, starting at 91-97% of the VT cycle length, decrementing thereafter [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] msec/pulse to a minimum pacing cycle length of 200-250 msec. The number of iterations selected in our population was one to four.
Cardioversion energies could be as low as 0.2 J ( Figure  7 ) and could be as high as 34 J. The term low energy cardioversion was reserved for pulses <1.0 J. The cardioversion pulsing technique was the same as that used for defibrillation. Pulsing methods included single-pulse, single-pathway monophasic (120-microfarod [,tF]) discharges; simultaneous-pulse, dual-pathway (120-,uF) discharges; or sequential-pulse, dual-pathway (two 60-tF) discharges. Cardioversion always followed unsuccessful antitachycardia pacing of VT. Cardioversion was selected as the initial intervention into VT only if antitachycardia pacing was proven ineffective. In patients with monomorphic VT cycle lengths shorter than the fibrillation detection interval, VT was treated with highenergy pulses as if it were VF.
As with cardioversion, defibrillation was possible with three different pulsing techniques. Energy output ranged between 0.2 and 34.0 J. Typically, initial defibrillation energy was programmed to twice the defibrillation threshold (Figure 8) . Thereafter, at least two pulses were programmed to the maximum output of 34 J.
Results
The clinical data are summarized in Table 1 . Forty-four of the 50 patients (88%) were men. The mean age was 57±16 years, with a range of 13-76 years of age. Twentyfour had coronary artery disease, nine had an idiopathic dilated cardiomyopathy, seven had both coronary artery disease and an idiopathic dilated cardiomyopathy, three had right ventricular dysplasia, two had hypertrophic cardiomyopathy, two had tetralogy of Fallot, two had primary electrical disease, and one had long QT syndrome. The mean ejection fraction was 0.38+0.17. The mean duration of patient follow-up was 15+5 months, with a range of follow-up of 8-24 months. The index arrhythmia leading to device implantation was VF in 23, VT in 21, and both VT and VF in six patients.
In the 35 patients receiving epicardial lead systems, a two-patch system was used in eight patients and a three-patch system was used in 27 patients. In the eight patients receiving a two-patch epicardial lead system, five had undergone previous cardiac surgery and underwent a lateral thoracotomy because of the previous sternotomy; one had a small heart, limiting epicardial surface area; one had a preexisting epicardial lead system at the time of pulse generator replacement; and one had a paper-thin, unresectable myocardial aneurysm, limiting epicardial access. In the 27 patients receiving a three-patch epicardial lead system, one patient underwent concomitant mitral valve replacement and eight had undergone previous cardiac surgery and underwent a lateral thoracotomy or subxyphoid incision for lead implantation. Whenever a three-patch epicardial lead system was used, the defibrillation method was always sequential pulse, dual pathway. The mean epicardial delivered energy defibrillation threshold using either two-patch or three-patch lead systems was 4.6+ 3.1 J, with a range of 1.0-15.0 J (Figure 9 ). The three-patch defibrillation threshold using sequential pulses was 4.1+3.1 J. The two-patch defibrillation threshold was 6.5±2.2 J.
A thoracotomy or sternotomy was avoided in 15 patients in whom a transvenous defibrillation lead system could be used. Implantation of a transvenous defibrillator was actually attempted in 16 patients, but one patient did not satisfy the protocol implant criterion of a defibrillation threshold of 20 J or less and subsequently received an epicardial lead system. The transvenous defibrillation lead system that was used varied and was dictated by the results of empirical intraoperative testing in which three to 15 different pulsing methods and/or lead systems were examined. Lead system selection also depended on the accessibility of the coronary sinus. The final lead configuration selected at the time of device implantation was an RV-CS-CP system in 10 of the 15 patients, an RV-SVC-CP lead system in three of 15, an RV-CP lead system in one of 15 and an RV-CS-EP lead system in one of 15 . The details of the 15 transvenous lead systems that were used are shown in Table 2 . Note that selected patients underwent defibrillation with a two-lead, single-pulse technique even though three leads were implanted. This was done to provide flexibility in device programming for unanticipated changes in cardiac function in the future. The delivered energy defibrillation thresholds at the time of implantation averaged 10.6+3.9 J for the transvenous system, with a range of 5.8-17.8 J.
In the one patient of the 16 patients who failed to receive a transvenous defibrillator, the minimum transvenous defibrillation threshold that could be attained was 25 J. This patient subsequently underwent implantation of an epicardial lead system in which a high defibrillation threshold was manifest as well. Sequential-pulse, dual-pathway defibrillation in this patient yielded a defibrillation threshold of 13.8 J.
Total patient survival and survival free of sudden cardiac death are shown in Figure 10 . Total patient survival was 96%, with no sudden arrhythmic deaths or surgical deaths, defined as death occurring 30 days after implantation. One patient died 3.5 months after device implantation from a bowel infarction after a mesenteric embolus associated with a previously unrecognized cancer. Another patient died 4 months after implantation from an inadvertent drug overdose.
Procedural or device-related complications arose in one patient receiving an epicardial unit and in three patients receiving a transvenous unit. One patient with an epicardial lead system developed an epicardial screw-in sensing lead fracture 1.5 years after implantation, which led to oversensing of myopotentials and delivery of VF therapy during sinus rhythm. Placement of an endocardial bipolar sensing lead alleviated the problem. One patient with a transvenous lead system had a CS lead that would not stay in position despite reapplication. Ultimately, this lead was positioned in the SVC, where it functioned satisfactorily. This same patient also developed a transient long thoracic nerve injury and winged scapula, presumably related to a jugular venous cannulation during surgery for anesthesiology care. Another patient also suffered a CS lead dislodgment the day after implant. In this case, however, the lead was restored to the CS location, remaining in place chronically. In one patient, an RV lead dislodgment occurred. This was observed in our first transvenous implant and was due to a loosely applied anchoring sheath. The lead was better secured upon repositioning.
Nine of 50 patients (18%) were spared the need for insertion of a separate bradycardia pacemaker because of the capability of the device for providing VVI pacing. Two patients were pacemaker dependent and used VVI pacing chronically. Seven patients had episodic bradyarrhythmias requiring only intermittent pacing support.
Antiarrhythmic drugs were not used in 41 of the 50 patients (82%) after device implantation. Twenty-seven of the 50 patients (54%) had been on antiarrhythmics before implantation. In 22 of these 27 patients, antiarrhythmic drugs could be withdrawn as a consequence of device function. Drugs were maintained in five of the 27 patients to minimize device intervention into very frequently occurring VT. In 23 patients, no antiarrhythmic drugs had been administered before device implantation because they presented shortly after their index cardiac arrhythmia. Four of these 23 patients were subsequently placed on antiarrhythmics as part of an LVEF, left ventricular ejection fraction; M, male; F, female; VF, ventricular fibrillation; VT, ventricular tachycardia; CAD, coronary artery disease; EP, epicardial patch; PED, primary electrical disease; CHD, congenital heart disease; RVD, right ventricular dysplasia; HCM, hypertrophic cardiomyopathy; IDCM, idiopathic dilated cardiomyopathy; LQTS, long QT syndrome; RV, right ventricular; CS, coronary sinus; CP, subcutaneous chest patch; SVC, superior vena cava; Single, single pathway; Sim, simultaneous pathways; Seq, sequential pathways; N/A, not available. *Selected patients underwent cardioversion/defibrillation with a two-lead, single-pulse technique even though three leads were implanted. This was done to provide flexibility in device programming in anticipation of possible changes in cardiac function in the future.
tLetters to the left of colon indicate location of the lead serving as the common cathode; letters to the right indicate location of lead(s) serving as anode(s). confirmation algorithm prevented therapy. Another five of the 15 episodes were accelerated into VF by VT cardioversion therapies; all were subsequently terminated by VF therapies (Figure 10 ). In three of these five patients, VT accelerated to VF with high-energy cardioversion (18 J in each case), whereas the other two accelerated with low energy (0.2 J and 1.0 J). Another five of the 15 VT episodes that were unsuccessfully treated were incessant in nature and required antiarrhythmic drug administration. All five of these episodes were treated with all four programmed VT therapies, but these therapies neither terminated nor accelerated the VT. Each episode occurred in a different patient. Three of these five episodes occurred in the perioperative period, and two episodes occurred with the patients at home. All were electively cardioverted from hemodynamically stable VT after drug administration.
In 19 of the 50 patients (38%), the device treated 144 spontaneous tachyarrhythmias as VF. True VF was determined to be present in 15 of these 144 episodes (10%). Rapid monomorphic VT with cycle lengths falling within the fibrillation detection zone was seen in 110 of the 144 episodes of VF (76%). These 110 rapid VT episodes were successfully treated with high-energy pulses. Ten episodes of VF (9%) were due to rapid AF. Inappropriate treatment of AF was in large measure a consequence of programming the FDI too conservatively. These episodes all occurred in patients in whom the FDI was programmed in the 320-380 msec range. Subsequent inappropriate therapy of AF was avoided by decreasing the FDI. Seven episodes of VF (5%) derived from one patient with an epicardial lead fracture. In his case, skeletal muscle myopotentials triggered therapy. An endocardial pace/sense lead corrected the problem. Two episodes of VF (1%) were the consequence of oversensing because of a high sensitivity setting. Oversensing was eliminated by reprogramming sensitivity. Despite these examples of inappropriate VF therapy, all patients with true VF or fast VT were successfully treated, and no morbidity was associated with inappropriate therapy.
The stability function was used to discriminate AF from VT in 11 of the 50 patients (22%) ( Figure 5 ). Six had paroxysmal AF and five had chronic AF. The interval stability parameter was 60 msec in seven patients and 40 msec in four. The number of consecutive intervals required to detect VT was programmed to 16 in five patients. In five patients, in addition to using the stability criterion, it was necessary to increase the number of consecutive intervals required for VT detection to 20 in two patients and to 24 in three patients to avoid treating AF as VT.
Discussion
The results of this study show that a multiprogrammable antiarrhythmia device can provide significant advantages in the management of patients with VT or VF. One of the most important advances is the ability to terminate VT with overdrive ventricular pacing. This has allowed us to minimize antiarrhythmic drug usage and avoid the attendant side effects, expense, and proarrhythmic potential of drugs.24 '25 It is now our practice to initiate antiarrhythmic drugs only in those patients who have very frequent episodes of VT that cannot be terminated with antitachycardia pacing or with low-energy cardioversion that is not painful. In those patients with primary VF instead of VT, the recurrence of VF is infrequent enough, occurring less than once every 2 years on average,26 to make antiarrhythmic drug therapy of questionable value, especially given the controversy over antiarrhythmic drug efficacy in preventing recurrent VF.27 Thus, unless episodes of VF became troublesomely frequent (as yet unseen in our patient population), the use of device therapy alone has proven sufficient.
The value of antitachycardia pacing as a painless means of terminating monomorphic VT has been recognized for many years. 22, [28] [29] [30] [31] [32] [33] [34] [35] In our population, it was possible to terminate 80% of spontaneously occurring VT episodes with antitachycardia pacing. This was a substantial advantage to those patients with monomorphic VT improving their quality of life. Unfortunately, antitachycardia pacing could not terminate all episodes of monomorphic VT.
Several reasons are postulated for why 20% of VT episodes, occurring in 12 of the 26 patients who had spontaneous VT, were not terminated by antitachycardia pacing. One reason is simply that antitachycardia pacing inefficacy may merely reflect the inability to examine all conceivable pacing modalities for each VT in each patient. Other causes of antitachycardia pacing failure may be rooted in the underlying VT mechanism, the supervening effect of new cardiac medications, changes in left ventricular function, and/or worsening coronary disease. Evolution in the arrhythmogenic substrate over time may alter the response to a particular overdrive pacing maneuver that appeared to be effective earlier in the patient's course.
Cardioversion was sometimes used instead of antitachycardia pacing for monomorphic VT because of limitations in the ability of the device to discriminate between rapid VT and VF. Attempting antitachycardia pacing into relatively short cycle length monomorphic VT would require setting the FDI too short, potentially compromising VF detection. For example, if one were to program the FDI to 260 msec to allow moderately rapid VT with a cycle length of 270 msec to fall within the VT detection zone, VF detection then becomes limited unless the patient happens to have VF with extremely short cycle lengths. The spectrum of VF cycle lengths is quite variable, not only from patient to patient but within each patient from episode to episode.17 '18 Thus, in order to not undersense VF, we were required in 60% of 33 patients with monomorphic VT occurring before or after device implantation to keep the FDI relatively long, typically 280-300 msec, and to force cardioversion of monomorphic VT with a short cycle length rather than risk undersensing VF. This led to our high incidence of VF therapy for VT.
A final comment about antitachycardia pacing is relevant with respect to time constraints. Practically, no more than five attempts at pace termination of VT were made before progressing to cardioversion. The decision to limit the number of pacing attempts to no more than five was based on the clinical consideration of limiting VT duration to a maximum of 1 minute before definitive high-energy cardioversion would be used. The device was capable of attempting as many as 60 antitachycardia pacing maneuvers, if so desired, but excessive intervention not only ran the risk of prolonged hypotension but also posed problems for successful detection and termination of VF should it follow VT. Overall, antitachycardia pacing proved to be a significant advancement in our patients. Although not all individuals with monomorphic VT were responsive to antitachycardia pacing, it is anticipated that further advances in detection schemes and in pacing techniques will allow more episodes of VT to be treated without resorting to cardioversion.
In patients in whom antitachycardia pacing proved ineffective, low-energy cardioversion was a reasonable alternative and was used in five of 35 of our patients (14%) in whom VT therapies were enabled. It should be recognized, however, that low-energy cardioversion for monomorphic VT was reserved for use when antitachycardia pacing was known to be ineffective and when cardioversion was clearly shown to not accelerate VT during postimplant electrophysiology studies.36 Although not entirely free of discomfort,37 low-energy shocks, especially those of 0.2-0.4 J, were minimally uncomfortable compared with high-energy shocks, according to our patients. In a few patients, these pulses went unnoticed.
Newer-generation multiprogrammable antiarrhythmic devices are also capable of treating bradyarrhythmias as well as tachyarrhythmias.2 7 In 18% of our patient population, standard-demand bradycardia pacemakers were avoided because of the ability of these newer units to perform VVI pacemaker function as well. The problem of providing dual-chamber or rateresponsive pacing remains unaddressed in the present generation of devices; yet, no patient in our population required both a dual-chamber pacemaker and a defibrillator. Seven of the nine patients in whom bradycardia pacing was used had episodic and infrequent transient AV block or sinus slowing. Two patients proved to be pacemaker dependent but had no apparent limitation from standard VVI pacing. Thus, it appears that simple backup bradycardia pacing is a useful and sufficient addition to such devices for the majority of individuals who need bradycardia pacing support.
Another advantage of the newer-generation antiarrhythmia devices is the ability to select patient-specific detection parameters. Programming can be done to take advantage of the differences in the detection algorithms for VT and VF. For example, patients with frequent episodes of nonsustained, asymptomatic VT do not necessarily require therapy. The principal concern in these individuals is that nonsustained VT will progress to VF or to sustained VT. By having the device notice only relatively long runs of VT, for example, >20 intervals, one can avoid unnecessary device intervention into most episodes of nonsustained VT.
VT detection could also be improved by the addition of a stability algorithm. By requiring tachycardia cycle length stability, it is possible to forgo intervention into AF in most cases. The combined requirements of a cycle length stability criterion, typically 40-60 msec, and a consecutive interval-to-interval count criterion within the VT detection zone have improved the specificity of VT detection.
In the case of VF, the detection scheme reflects the design intention to be highly sensitive to the presence of VF, preferentially sacrificing VF detection specificity. An auto-adjusting sensitivity threshold enhances VF detection sensitivity by adjusting to fluctuations in VF electrogram amplitude and minimizing undersensing when small-amplitude signals are interposed between large-amplitude ones.20,21,38-40 Simultaneously, detection of VF is improved by requiring that only 75% of the signals during VF be observed by the device in order to declare VF present. Both of these detection tools (auto-adjusting sensitivity threshold and percentage of signal detection) are intended to facilitate VF recognition preferentially compared with VT recognition.
This study has also demonstrated that one of the principal limitations of antiarrhythmia device use, the requirement of a sternotomy or thoracotomy, can be avoided. This has already been demonstrated to be possible by several other investigators.741-43 Our experience is equally favorable. In 15 patients, antiarrhythmic devices with transvenous lead systems were inserted, circumventing open-chest surgery. The only limitation with this approach thus far has been the occurrence of lead dislodgments observed in three patients. These occurrences represent in large measure our relative inexperience with this new approach. Such problems are likely to yield to advances in lead design as well as to continued physician experience, as has been the case with dual-chamber bradycardia pacing lead systems.
Conclusions
Tiered-therapy, multiprogrammable devices offer substantial advantages in the management of patients with VT and VF. However, this type of therapy is complex and requires frequent reassessment by the managing physician to ensure appropriate device programming, especially for patients in whom antitachycardia pacing maneuvers are used. The complexity of the device notwithstanding, the possibility of avoiding painful or inappropriate shocks, antiarrhythmic drugs, and open-chest surgery suggest that these devices will have an increasingly important role in the care of patients with cardiac arrhythmias.
